Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:
- A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
- An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025
The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.